further analysis of response trial data validates ruxolitinib as second-line therapy
Published 9 years ago • 335 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
4:17
pv: treatment with ruxolitinib
-
1:32
response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
-
5:50
case 2: the response trial of ruxolitinib for pv
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
3:09
real-world data analysis of ruxolitinib in myelofibrosis
-
1:44
follow up of the phase 3 response trial of ruxolitinib in polycythemia vera
-
3:49
utilization of ruxolitinib for polycythemia vera
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
1:46
results for the follow-up of the response study
-
1:18
dr. ruben mesa discusses the comfort ruxolitinib trials
-
3:55
response to ruxolitinib therapy for polycythemia vera
-
3:34
a response to ruxolitinib: update on 4-year trial follow-up
-
0:31
exploring the benefits of ruxolitinib in second-line polycythemia vera
-
5:19
pivotal ruxolitinib data shows promise for patients with pv
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
4:26
polycythemia vera: switching therapy
-
4:31
ruxolitinib for treatment of polycythemia vera
-
2:30
dr. harrison on 5-year follow-up data on ruxolitinib in patients with myelofibrosis
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis